T2 Biosystems Inc (NASDAQ:TTOO) had a decrease of its short interest by 0.63%. It was announced in March by FINRA the 2.84 million short interest on TTOO. That’s 0.63% down from 2.86 million shares. T2 Biosystems Inc (NASDAQ:TTOO) has 252,400 shares average volume. It’ll cost 11 days for TTOO to restore its former position.

Ticker’s shares touched $2.71 during the last trading session after 5.86% change.T2 Biosystems, Inc. is downtrending after having declined 15.55% since March 21, 2018. TTOO has 1.69 million volume or 149.53% up from normal. TTOO underperformed by 19.92% the S&P 500.

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States.The firm is valued at $120.11 million. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine.Currently it has negative earnings. The firm also offers T2Dx, a bench-top instrument for sepsis, Lyme disease, and other applications, as well as T2Candida panel for the detection of candida species in human whole blood specimens.

T2 Biosystems, Inc. (NASDAQ:TTOO) Ratings Coverage

In total 3 analysts cover T2 Biosystems (NASDAQ:TTOO). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 6 are the (NASDAQ:TTOO)’s analyst reports since February 27, 2019 according to StockzIntelligence Inc. The company rating was maintained by Cantor Fitzgerald on Tuesday, March 5. On Thursday, February 28 the stock has “Buy” rating by H.C. Wainwright. On Tuesday, March 5 the company was maintained by Canaccord Genuity. On Wednesday, February 27 the firm has “Buy” rating by Cantor Fitzgerald given. In Friday, March 8 report H.C. Wainwright maintained it with “Buy” rating and $11 target.

For more T2 Biosystems, Inc. (NASDAQ:TTOO) news brought out briefly go to: Seekingalpha.com, Benzinga.com, Benzinga.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “TrovaGene leads healthcare gainers; CHF Solutions and Altimmune among the losers – Seeking Alpha” brought out on March 08, 2019, “Daily Biotech Pulse: Tonix Gets European Patent, EC Nod For Roche, Insys Earnings – Benzinga” on March 08, 2019, “70 Biggest Movers From Friday – Benzinga” with a publish date: March 11, 2019, “FDA grants accelerated review for T2 Bio’s genetic pathogen panel; shares up 26% after hours – Seeking Alpha” and the last “Why Hospitals Are Not Buying The T2 Biosystems Diagnostic System – $1.50 1-Year Price Target – Seeking Alpha” with publication date: March 05, 2019.